Subscribe To Our Free Newsletter |
Glenmark Pharmaceuticals Limited – Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated September 15, 2015 titled ''Glenmark's Bi-Specific Antibody - GBR 1302 to enter Phase I trials''......